Asset Details
Do you wish to reserve the book?
Harnessing artificial intelligence to identify Bufalin as a molecular glue degrader of estrogen receptor alpha
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Harnessing artificial intelligence to identify Bufalin as a molecular glue degrader of estrogen receptor alpha
Do you wish to request the book?
Harnessing artificial intelligence to identify Bufalin as a molecular glue degrader of estrogen receptor alpha
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Harnessing artificial intelligence to identify Bufalin as a molecular glue degrader of estrogen receptor alpha
2025
Overview
Target identification in natural products plays a critical role in the development of innovative drugs. Bufalin, a compound derived from traditional medicines, has shown promising anti-cancer activity; however, its precise molecular mechanism of action remains unclear. Here, we employ artificial intelligence, molecular docking, and molecular dynamics simulations to elucidate the molecular mechanism of Bufalin. Using an integrated multi-predictive strategy, we identify CYP17A1, ESR1, mTOR, AR, and PRKCD as the potential targets of Bufalin. Subsequent validation via surface plasmon resonance, biotin pulldown, and thermal shift assays confirms Bufalin’s direct binding to ESR1, which encodes estrogen receptor alpha (ERα). Molecular docking analyses pinpoint Bufalin’s selective interaction with Arg394 on ERα. Molecular dynamic simulations further show that Bufalin acts as a molecular glue, enhancing the interaction between ERα and the E3 ligase STUB1, thereby promoting proteasomal degradation of ERα. Given the therapeutic potential of ERα degradation in overcoming endocrine resistance, we investigate the inhibitory effect of Bufalin on endocrine-resistant models and prove Bufalin reverses Tamoxifen resistance in vitro, in vivo, and in patient-derived breast cancer organoids from tamoxifen-relapsed cases. Collectively, our findings indicate that Bufalin functions as a molecular glue to degrade ERα, offering a potential therapeutic strategy for reversing Tamoxifen resistance.
Target identification of natural products plays a critical role in the development of innovative drugs. Here, this group integrates molecular docking and molecular dynamics simulations on Bufalin and reports the potential targets as well as its role in reversing endocrine resistance.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 14/19
/ Animals
/ Antineoplastic Agents - pharmacology
/ Biotin
/ Breast Neoplasms - drug therapy
/ Breast Neoplasms - metabolism
/ Breast Neoplasms - pathology
/ Drug Resistance, Neoplasm - drug effects
/ Drugs
/ Estrogen Receptor alpha - chemistry
/ Estrogen Receptor alpha - genetics
/ Estrogen Receptor alpha - metabolism
/ Female
/ Humanities and Social Sciences
/ Humans
/ Mice
/ Molecular Docking Simulation
/ Molecular Dynamics Simulation
/ Proteins
/ Science
